Verrica Pharmaceuticals Inc. (VRCA)

Market Cap	40.47M
Revenue (ttm)	9.21M
Net Income (ttm)	-84.99M
Shares Out	45.60M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,422
Open	0.890
Previous Close	0.890
Day's Range	0.850 - 0.920
52-Week Range	0.704 - 11.410
Beta	1.46
Analysts	Buy
Price Target	7.33 (+726.01%)
Earnings Date	Nov 4, 2024

About VRCA

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which include...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: VRCA
• Website: https://www.verrica.com

Financial Performance

In 2023, Verrica Pharmaceuticals's revenue was $5.12 million, a decrease of -43.27% compared to the previous year's $9.03 million. Losses were -$67.00 million, 173.6% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for VRCA stock is "Buy." The 12-month stock price forecast is $7.33, which is an increase of 726.01% from the latest price.

Price Target

$7.33

(726.01% upside)

Analyst Consensus: Buy